Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-PKD: Dapagliflozin in Autosomal Dominant Polycystic Kidney Disease
NCT07280585Phase 3Recruiting
- Sponsor
- University of Cologne
- Start
- Dec 2025
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of dapagliflozin in autosomal dominant polycystic kidney disease (ADPKD), sponsored by University of Cologne. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07280585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280585.